NCPE resubmission and revised offer
Rebuilt the clinical and budget impact case for an NCPE resubmission, then supported the revised commercial offer.
Our work
HTA, HEOR and access work, from oncology to rare disease.
A selection of the HTA, HEOR, market access, policy and global health work we deliver. Client names and products stay confidential.
Inside the HTA process
Led by a former NICE HTA Technical Lead and Analyst, who knows how committees read a submission.
Across HTA systems
NICE, SMC, AWMSG, NCPE, CDA‑AMC and the EU JCA, plus US pricing work.
Senior-led
The person who scopes your project builds the model and joins the meeting.
In health since 2015
More than a decade across clinical practice, public health, agencies and HTA.
Selected engagements
Filter by the work you need.
Joint clinical assessment dossiers
PICO scoping, indirect treatment comparisons and network meta-analyses for JCA dossiers across several companies.
Appraisals from inside the committee process
HTA Technical Lead and Analyst on appraisals in ophthalmology, hepatology, cardio-renal, haematology, and cell and gene therapy.
Most-favoured-nation pricing
International price referencing analysis to show how MFN policy could move net prices across markets.
Global model adaptations
Cost-effectiveness and budget impact models adapted for UK, Irish, EU, Canadian and US settings in Excel/VBA, R and Python.
Programme design and evaluation
Programme design, monitoring, research and evaluation with UN agencies, international NGOs and research institutions.
HealthTech guidance and evidence reviews in cardiovascular care.
Appraisal teams in ophthalmology, hepatology, cardio-renal, haematology, and cell and gene therapy.
Multiple NHS use cases for emerging health technologies.
Submissions and budget impact models for advanced therapies, oncology and rare diseases.
Resubmissions and revised commercial offers after negative recommendations.
Reimbursement review projects for Canada's Drug Agency (formerly CADTH).
JCA dossiers for multiple companies, with PICO scoping, ITCs and NMAs. See our JCA Readiness Index.
Most-favoured-nation pricing and international price referencing projects.
De novo and global adaptations of cost-effectiveness, cost-utility, cost-comparison and budget impact models in Excel/VBA, Python and R.
De novo SLRs and SLR updates for submissions in oncology, respiratory, immunology, women's health and devices.
Mapping of AI use cases across international HTA bodies. Read our analysis.
Product advisory boards for pharma, biotech and MedTech companies.
Programme design, monitoring, research and evaluation with UN agencies, international NGOs and research institutions.
Policy analysis, advocacy and health communications for public health programmes and patient groups.
Therapy areas
From common cancers to ultra-rare disease.
A selection of conditions we have modelled, reviewed or assessed in company submissions, HTA assessments and advisory work. Products and clients stay confidential.
Therapy area
Oncology
Solid tumours, from first-line targeted therapy to rare and paediatric cancers.
Tap a condition to see how we can help.
Therapy area
Haematology and cell therapy
Blood cancers, bleeding disorders and haemoglobinopathies, including CAR-T and gene editing.
Tap a condition to see how we can help.
Therapy area
Rare disease and advanced therapies
Orphan and ultra-orphan conditions, gene therapies and small populations where evidence is thin.
Tap a condition to see how we can help.
Therapy area
Neurology and mental health
Progressive and episodic neurological conditions, and digital therapeutics.
Tap a condition to see how we can help.
Therapy area
Immunology and dermatology
Chronic inflammatory and eosinophilic disease.
Tap a condition to see how we can help.
Therapy area
Gastroenterology and hepatology
Inflammatory bowel disease and cholestatic liver disease.
Tap a condition to see how we can help.
Therapy area
Respiratory and allergy
Chronic airway disease and allergen immunotherapy.
Tap a condition to see how we can help.
Therapy area
Cardiovascular
Structural heart interventions and cardiac diagnostics.
Tap a condition to see how we can help.
Therapy area
Renal, metabolic and endocrine
Long-term conditions where budget impact matters as much as cost-effectiveness.
Tap a condition to see how we can help.
Therapy area
Women's health
Gynaecological, menopausal and maternal health.
Tap a condition to see how we can help.
Therapy area
Infectious disease
Prevention and treatment of viral infection.
Tap a condition to see how we can help.
Therapy area
Ophthalmology
Inherited optic nerve disease and glaucoma.
Tap a condition to see how we can help.
Therapy area
Diagnostics, MedTech and digital health
Diagnostic pathways, devices and digital tools, including return-on-investment cases.
Tap a condition to see how we can help.
HTA bodies
- NICE (England)
- SMC and AWMSG
- NCPE and HSE (Ireland)
- EU JCA
- CDA-AMC (Canada)
- US pricing (MFN)
Methods
- Partitioned survival, Markov, microsimulation
- Budget impact and cost-comparison
- NMA, MAIC and ITC
- Structured expert elicitation
Tools
- Excel and VBA
- R and R Shiny
- Python
- Validated AI-assisted workflows
Start a conversation
Want to know if we have done your type of project?
Start with a free, no-obligation 30-minute call with a senior consultant.